Trial reportEuropean journal of clinical pharmacology2004
Bioavailability of fluticasone propionate and mometasone furoate aqueous nasal sprays.
Trial report in European journal of clinical pharmacology, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 76 citations in OpenAlex.
- Bioavailability and disposition of azelastine and fluticasone propionate when delivered by MP29-02, a novel aqueous nasal spray.British journal of clinical pharmacology · 2012Trial
- Intranasal drug delivery to the brain for neurodegenerative diseases: Current efforts and challenges in delivery platforms and modeling.Advanced drug delivery reviews · 2026Review
- Safety Profile of Intranasal Corticosteroids in Allergic Rhinitis: A Comprehensive Review.Biomedicines · 2026Review
- Intranasal Corticosteroids: Topical Potency, Systemic Activity and Therapeutic Index.Journal of asthma and allergy · 2021Review
- Scientific Considerations for the Review and Approval of First Generic Mometasone Furoate Nasal Suspension Spray in the United States from the Bioequivalence Perspective.The AAPS journal · 2019Article
- Safety of intranasal corticosteroid sprays during pregnancy: an updated review.European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery · 2018Review
- Small Airway Absorption and Microdosimetry of Inhaled Corticosteroid Particles after Deposition.Pharmaceutical research · 2017Article
- Linking Suspension Nasal Spray Drug Deposition Patterns to Pharmacokinetic Profiles: A Proof-of-Concept Study Using Computational Fluid Dynamics.Journal of pharmaceutical sciences · 2016Article
- Absorption and Clearance of Pharmaceutical Aerosols in the Human Nose: Effects of Nasal Spray Suspension Particle Size and Properties.Pharmaceutical research · 2016Article
- Comparison of the ligand binding site of CYP2C8 with CYP26A1 and CYP26B1: a structural basis for the identification of new inhibitors of the retinoic acid hydroxylases.Journal of enzyme inhibition and medicinal chemistry · 2016Article
- Inhaled corticosteroids: potency, dose equivalence and therapeutic index.British journal of clinical pharmacology · 2015Review
- The need for patient-focused therapy for children and teenagers with allergic rhinitis: a case-based review of current European practice.Clinical and translational allergy · 2015Article
- Article
- Allergic conjunctivitis and the impact of allergic rhinitis.Current allergy and asthma reports · 2010Review
- Mechanisms and clinical implications of glucocorticosteroids in the treatment of allergic rhinitis.Clinical and experimental immunology · 2009Review
- Review
- Mometasone furoate nasal spray: a review of safety and systemic effects.Drug safety · 2007Review
- Safety of intranasal corticosteroids in acute rhinosinusitis.American journal of otolaryngologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTo compare the systemic exposure for intranasal mometasone furoate (MF) and fluticasone propionate (FP) aqueous nasal sprays (ANS) in terms of serum and urinary cortisol parameters and plasma pharmacokinetics.
methodsTwelve healthy subjects completed this three-way, cross-over study. They received FPANS (50 microg/spray), MFANS (50 microg/spray) or placebo ANS, eight sprays per nostril every 8 h for 4 days. Cortisol measurements were made at baseline and day 4. FP and MF plasma concentrations were also measured on day 4.
resultsMFANS produced similar mean plasma AUC (123 pmol/l h) to FPANS (112 pmol/l h). Despite the use of high doses, necessary to generate adequate pharmacokinetic data, only minor reductions in cortisol parameters were found, with no difference between FPANS and MFANS.
conclusionsFP and MF have similar and very low systemic bioavailability when administered intranasally using a high-dose regimen. It is therefore unlikely that therapeutic doses of intranasal FP or MF will produce dissimilar or significant degrees of systemic exposure or systemic effects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.